Wai Yuen Tong Medicine Holdings Limited

Wai Yuen Tong Medicine Holdings Limited

HHKEX:897
0.37
HKD
-0.01
(-2.67%)
367.75MMarket Cap
Wai Yuen Tong Medicine Holdings Limited
HKEX:897
(Hong Kong Exchange)

Recent

price

0.37

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
HKD
8.35
6.25
6.17
4.47
3.11
1.65
0.84
0.67
0.6
0.5
0.9
1.13
0.59
0.66
0.66
0.61
- -
Revenue per Share
1.29
-1.84
1.17
0.84
0.45
0.05
-0.11
-0.09
0.06
0.36
-0.31
-0.09
-0.02
-0.01
0.01
- -
- -
Basic EPS, GAAP
-1.48
-0.06
-0.35
-0.21
-0.85
-0.8
-0.19
-0.11
-0.03
-0.03
0.29
0.12
0.11
0.13
0.07
0.05
- -
Free Cash Flow per Basic Share
- -
0.05
- -
0.05
0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.18
- -
- -
Dividend per Share
13.26
11.49
9.69
10.59
8.18
6.48
2.1
2.02
1.98
2.15
2.08
2.04
1.95
1.18
1.05
1.06
1.06
Book Value per Share
13.12
11.36
9.6
10.5
8.12
6.44
2.08
2.01
1.98
2.15
2.08
2.04
1.95
1.18
1.05
1.06
1.06
Tangible Book Value per Share
77
120
127
194
267
499
883
1,265
1,248
1,232
1,232
1,232
1,216
1,181
1,126
1,125
1,125
Basic Weighted Avg Shares
640
752
786
865
831
825
738
846
751
621
1,109
1,391
724
784
745
683
- -
Sales/Revenue/Turnover
7.08
5.46
2.88
2.95
-6.72
-8.13
-17
-12.93
-19.48
-20.36
3.85
5.27
1.59
5.09
-4.25
-2.47
- -
Operating Margin (%)
11
14
17
19
15
15
14
47
51
113
93
108
113
111
90
84
- -
Depreciation Expense
99
-221
148
163
121
25
-93
-116
75
439
-376
-109
-21
-15
7
4
- -
Net Income, GAAP
16.46
- -
0.2
2.14
0.01
13.21
- -
- -
9.12
3.78
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
15.5
-29.36
18.89
18.88
14.56
3.08
-12.64
-13.67
9.93
70.65
-33.92
-7.83
-2.84
-1.96
0.95
0.58
- -
Profit Margin (%)
379
374
626
546
440
508
651
639
968
1,222
862
1,007
1,045
449
262
170
170
Working Capital
85
71
40
189
351
580
697
662
620
1,148
900
1,041
1,032
276
156
- -
- -
LT Debt
1,602
1,390
1,685
1,841
2,046
2,330
2,658
2,560
2,448
3,993
3,950
3,961
3,688
1,385
1,180
1,181
1,181
Total Equity
2.62
- -
3.12
3.91
0.68
0.49
- -
- -
-1.7
10.07
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
7.37
- -
8.69
8.19
5.45
1.36
- -
- -
2.97
10.61
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
7.36
-14.84
9.7
9.31
6.25
1.16
-3.75
-4.44
2.99
17.24
-14.44
-4.29
-0.84
-0.82
0.55
0.34
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
279
301
338
LT Borrowings
156
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,125
1,125
1,114
Market Capitalization
405
484
368

Working Capital

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
621
614
599
Cash, Cash Equivalents & STI
147
136
147
Accounts Receivable, Net
67
63
55
Inventories
238
238
227
Total Current Liabilities
359
482
429
Payables & Accruals
- -
- -
- -
ST Debt
279
301
338
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.57%
-16.77%
0.08%
Free Cash Flow
-127.59%
-25.03%
-24.24%
Net Income, GAAP
-67.36%
-73.47%
-43.77%
Sales/Revenue/Turnover
2.67%
-5.48%
-8.3%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
784
2025
- -
- -
745
2026
- -
- -
683

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.18
2026
- -
- -
- -
Business
Wai Yuen Tong Medicine Holdings Limited is an investment holding company engaged in the production and sale of Chinese and Western pharmaceuticals and health food products primarily in Hong Kong, Mainland China and Macau. The company manufactures, processes and sells traditional Chinese medicines under the Wai Yuen Tong brand, including flagship over-the-counter products such as Hou Tsao Powder (猴棗除痰散), Angong Niuhuang Wan (安宮牛黃丸), Young Yum Pills (養陰丸), White Phoenix Pills (白鳳丸), Wild Cordyceps Plus (野生蟲草皇), Nano Bone Enhancer (骨盈素), Premium Ganoderma Eight Plus (百草靈芝皇), Body Dampness Relief (祛濕清) and Ultimate Brightening (雪肌丸); provides Traditional Chinese Medicine (TCM) consultation services and management and promotion services; and produces Western pharmaceutical and personal care products under the Madame Pearl’s brand, notably cough syrup which holds the number one market position in Hong Kong for 15 consecutive years, and the Pearl’s brand. It also invests in commercial and retail properties for rental income. Founded in 1897 and headquartered in Kowloon Bay, Hong Kong, the company operates through a network of retail stores under self-operating and franchise models, integrated TCM healthcare centres, and e-commerce channels including cross-border platforms like Douyin; it is a subsidiary of Rich Time Strategy Limited with 759 employees as of March 2025. Recent developments include the October 2025 approval of Hou Tsao Powder as Hong Kong's first traditional oral proprietary Chinese medicine for Mainland China listing under the Greater Bay Area simplified OTC registration scheme, enabling market entry in 2026; substantial 154% growth in cross-border e-commerce sales for the six months ended September 2025 driven by enhanced marketing and distribution; launch of new products like Body Dampness Relief which became a top-selling health supplement; introduction of AI TCM diagnostic systems and CRM upgrades at premier stores; expansion of Madame Pearl’s distribution to over 40,000 outlets in Mainland China including hospitals and e-pharmacies; property disposals yielding HK$153.4 million in considerations during fiscal 2025 including Shops in Tsuen Wan, Nathan Road, Kwun Tong, Aberdeen and Yen Chow Street; and no dividend recommendation for fiscal 2025 amid a shift to profit of HK$7.1 million attributable to owners after prior-year loss.